<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123170</url>
  </required_header>
  <id_info>
    <org_study_id>2/2020ANET11</org_study_id>
    <nct_id>NCT05123170</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in IVRA</brief_title>
  <official_title>Comparison of Two Different Doses of Dexmedetomidine Added to Lignocaine in Patients Posted for Upper Limb Orthopedic Surgery Under Intravenous Regional Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mohamed Abodief Mohamed Ahmed</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ayman Ahmed Radi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sadik Abdel Maseeh Sadik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized controlled double-blinded study will be conducted on 90 patients&#xD;
      assigned randomly into three equal groups,&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining approval of the medical and ethical committee of Menoufia University &amp; Nasser&#xD;
      Institute for Research and Treatment, an informed and written consent from the patients, a&#xD;
      prospective controlled randomized double blinded study will be performed&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      MedCalc® version 12.3.0.0 program &quot;Ostend, Belgium&quot; was used for calculations of sample size,&#xD;
      statistical calculator based on 95% confidence interval and power of the study 80% with α&#xD;
      error 5%, According to a previous study (13), showed that the duration of tourniquet time in&#xD;
      group A was mean 51.60±5.157 and Group B was mean 53.80±4.773, with p-value &gt;0.05, while&#xD;
      Quality of block of excellent in group A 83.3% and group B 90%, it turns out that there is&#xD;
      success in the group B compared to group A, but there is no difference. So it can be relied&#xD;
      upon in this study, based on this assumption, sample size was calculated according to these&#xD;
      values produced a minimal samples size of 86 cases were enough to find such a difference.&#xD;
      Assuming a drop-out ratio of 5%, the sample size will be 90 cases, subdivided into three&#xD;
      groups 30 cases in each group. Patients will be randomly categorized into three equal groups&#xD;
      (30 patients each): The patients will be randomly allocated to one of these three groups,&#xD;
      using a computer-generated sequence of random numbers and a sealed envelope technique.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Actual">June 20, 2021</completion_date>
  <primary_completion_date type="Actual">March 25, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hollmen scale</measure>
    <time_frame>2 hours</time_frame>
    <description>change from base line for the scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modified bromage scale</measure>
    <time_frame>2 hours</time_frame>
    <description>change from baseline for the scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual analogue score</measure>
    <time_frame>2 hours</time_frame>
    <description>changes in the scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ramsey sedation score</measure>
    <time_frame>2 hours</time_frame>
    <description>changes in the scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Regional Anesthesia Morbidity</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) alone diluted with normal saline 0.9% to make the final volume 30 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.25 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3 mg/kg of 2% lignocaine (maximum dose 300 mg) plus dexmedetomidine 0.5 μg/kg diluted with normal saline 0.9% to make the final volume 30 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injectable Solution [Dexdomitor]</intervention_name>
    <description>two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries</description>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine IV</intervention_name>
    <description>Intravenous regional anaesthesia</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of ASA class I and II.&#xD;
&#xD;
          2. Patients of either sex.&#xD;
&#xD;
          3. Patients aged between 20-70 years.&#xD;
&#xD;
          4. Patients scheduled for forearm and hand surgery lasting for about 60 minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patient with known hypersensitivity to any study medications. 2. Patient with&#xD;
             Severe peripheral vascular disease and neurological disease. 3. Where use of&#xD;
             tourniquet will be either not possible or contraindicated. 4. Patient with Hemolytic&#xD;
             diathesis specially sickle cell anemia, epilepsy, diabetes mellitus, hypertension,&#xD;
             cardiovascular disease like myocardial infarction, cardiac arrhythmias, heart block&#xD;
             and altered mentation. 5. Procedures lasting for more than 90 min will be also not&#xD;
             considered. 6. Therapy with adrenergic receptor antagonist, calcium channel blocker&#xD;
             and ACE inhibitors. 7. Patient with impaired liver function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sadek AM Sadek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Menoufia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Menoufia University</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufia</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>mostafa saieed fahim mansour</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Lignocaine</keyword>
  <keyword>Upper Limb Orthopedic Surgery</keyword>
  <keyword>Intravenous Regional Anaesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

